Ticker Details
Syndax Pharmaceuticals, Inc. Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications.
IPO Date:	March 3, 2016
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.71B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.40 | 2.81%
Avg Daily Range (30 D):	$0.41 | 1.97%
Avg Daily Range (90 D):	$0.46 | 2.55%

Institutional Daily Volume
Avg Daily Volume:	.62M
Avg Daily Volume (30 D):	.97M
Avg Daily Volume (90 D):	1.83M

Trade Size
Avg Trade Size (Sh.):	86
Avg Trade Size (Sh.) (30 D):	63
Avg Trade Size (Sh.) (90 D):	77

Institutional Trades
Total Institutional Trades:	3,316
Avg Institutional Trade:	$2.29M
Avg Institutional Trade (30 D):	$2.46M
Avg Institutional Trade (90 D):	$2.18M
Avg Institutional Trade Volume:	.13M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$2.94M
Avg Closing Trade (30 D):	$3.36M
Avg Closing Trade (90 D):	$3.76M
Avg Closing Volume:	166.62K

News

Jan 7, 2026 @ 12:00 PM Syndax and World Orphan Drug Alliance to Launch a ... Source: Na

Dec 1, 2025 @ 12:00 PM Syndax Announces Participation at the 8th Annual E... Source: Michael A. Metzger

Oct 24, 2025 @ 5:58 PM Syndax Announces FDA Approval of Revuforj® (rev... Source: Syndax Pharmaceuticals

Oct 10, 2025 @ 8:54 AM Menin Inhibitors Drug Market Report 2025: Price, S... Source: Researchandmarkets.Com

Jul 28, 2025 @ 11:00 AM Syndax to Announce Second Quarter 2025 Financial R... Source: Sharon Klahre

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS		$-.7	$-.83
Diluted EPS		$-.7	$-.83
Revenue		$45.87M	$37.96M
Gross Profit
Net Income / Loss		$-60.72M	$-71.85M
Operating Income / Loss		$-57.43M	$-69.35M
Cost of Revenue
Net Cash Flow		$8.17M	$-45.36M
PE Ratio